Drug Research
Real World Data Optimizing Drug Formulation Decisions
The pharmaceutical industry is currently undergoing a data-driven revolution that is fundamentally changing how medications are designed and optimized. For decades, drug development was a linear process that culminated in randomized controlled trials (RCTs). While RCTs are essential for...
IT & Data Management
Quantum Computing Advancing Molecular Discovery Models
Harnessing the power of subatomic physics to simulate complex biological interactions at an atomic level, unlocking new frontiers in drug discovery and precision medicine through unprecedented computational speed.
IT & Data Management
Digital Therapeutics Expanding Pharmaceutical Care
Redefining patient treatment through clinically validated software interventions that complement or replace traditional medications, offering personalized, remote, and scalable care for chronic conditions.
IT & Data Management
Knowledge Graphs Improving Pharmaceutical Intelligence
Connecting disparate datasets into a unified semantic network to uncover hidden relationships between diseases, drugs, and genetic markers, accelerating discovery and operational decision-making.
IT & Data Management
Digital Product Passports Enhancing Pharma Traceability
Revolutionizing pharmaceutical supply chains through decentralized digital identities that track drug lifecycles from manufacturing to patient delivery, ensuring authenticity and regulatory compliance.
IT & Data Management
Synthetic Data Accelerating Clinical Development
Leveraging mathematically generated datasets to mirror real-world patient populations, enhancing trial efficiency while ensuring absolute privacy and regulatory compliance in modern drug research.
Business & Industry
Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation
Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















